Brief: Egetis Terminates Discussions Regarding Potential Acquisition, Provides Corporate Update

Egetis Therapeutics AB (publ)

24/05/2023 07:40

May 24 (Reuters) - Egetis Therapeutics AB  EGTX.ST :
    * SAID ON TUESDAY EGETIS ANNOUNCES TERMINATION OF
DISCUSSIONS
REGARDING POTENTIAL ACQUISITION OF CO, PROVIDES CORPORATE UPDATE
    * DISCUSSIONS HAVE NOW BEEN TERMINATED AS BOARD BELIEVES
CONTEMPLATED OFFER, TERMS, WHILE PROVIDING PREMIUM TO CURRENT
SHARE PRICE, CONSIDERABLY UNDERVALUED LONG-TERM PROSPECTS OF
COMPANY
    * TIMELINE FOR SUBMISSION OF MARKETING AUTHORISATION
APPLICATION
(MAA) FOR EMCITATE (TIRATRICOL) TO EUROPEAN MEDICINES AGENCY
(EMA) HAS BEEN EXTENDED FROM SECOND QUARTER TO EARLY AUTUMN OF
2023

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN5fPllr
 Further company coverage:  EGTX.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))